Company & Sponsor Intelligence
National Institute on Aging (NIA)
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials7
Recruiting1
Completed3
Countries1
Therapeutic footprint
alzheimers
Indexed studies
NCT01255163A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT07721467Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT00013923Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT00000178Multicenter Trial of Prednisone in Alzheimer's Disease
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT04871698On Site Sensors Monitoring Impacts of Cognitive Decline on ADLs
alzheimers · United StatesUNKNOWN
alzheimers · United StatesUNKNOWN
NCT01867359The Genetic Characterization of Dementia
alzheimers · United StatesCOMPLETED
alzheimers · United StatesCOMPLETED
NCT00094952Biomarkers and Early Alzheimer's Disease
alzheimers · United StatesUNKNOWN
alzheimers · United StatesUNKNOWN
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →